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Abstract: Streptococcus pneumoniae (SP) is a common human pathogen associated with a broad 14 
spectrum of diseases and it is still a leading cause of mortality and morbidity worldwide, especially 15 
in children. Moreover, SP is increasingly associated with drug resistance. Vaccination against the 16 
pathogen may thus represent an important strategy to overcome its threats to human health. In this 17 
context, revealing the molecular determinants of SP immunoreactivity may be relevant for the 18 
development of novel molecules with therapeutic perspectives as vaccine components. Serogroup 19 
19 comprises the immune-cross reactive types 19F, 19A, 19B and 19C and it accounts for a high 20 
percentage of invasive pneumococcal diseases, mainly caused by serotypes 19F and 19A. Herein, 21 
we report the synthesis and biological evaluation of an aminopropyl derivative of the trisaccharide 22 
repeating unit of SP 19A. We compare two different synthetic strategies, based on different 23 
disconnections between the three monosaccharides which make up the final trisaccharide, to define 24 
the best approach for the preparation of the trisaccharide. Synthetic accessibility to the trisaccharide 25 
repeating unit lays the basis for the development of more complex biopolymer as well as saccharide 26 
conjugates. We also evaluate the binding affinity of the trisaccharide for anti-19A and anti-19F sera 27 
and discuss the relationship between the chemical properties of the trisaccharide unit and biological 28 
activity. 29 
 30 
1. Introduction 31 
Streptococcus pneumoniae (SP) represents a relevant cause of infections associated with high 32 
mortality and morbidity: invasive pneumococcal disease (IPD) indeed still shows a high incidence 33 
especially in children and in the elderly. Capsular polysaccharides (CPSs) are the primary 34 
determinants of the pathogenicity of the bacterium, and account for the classification of SP in more 35 
than 90 serotypes.
1
 A limited subset of serotypes is responsible for the majority of pneumococcal 36 
infections, and representatives of such subsets are contained in commercial licensed vaccines (for 37 
example PCV7, Prevnar 7 - Wyeth Pharmaceuticals, contains serotypes 4, 6B, 9V, 14, 18C, 19F and 38 
23F). Indeed, capsular polysaccharides (CPSs) are immunogenic, and the generation of type-39 
specific antibodies to CPS is protective.
2
 The pattern of predominant IPD associated serotypes, 40 
subjected to a natural fluctuation over time, contains also serotypes of low immunogenicity, such as 41 
6, 14, 19 and 23, where low immunogenicity unfortunately does not equate to low virulence, 42 
especially in immune-naive hosts.
3
 Consequently, a lower vaccination efficacy has been observed 43 
for these serotypes.
4
 This is probably not associated to the absolute antibody concentration 44 
generated by the vaccine towards each single different serotype, but, more likely, to the increased 45 
amount of antibodies required for killing less immunogenic serotypes. Serogroup 19, which 46 
comprises the immune-cross reactive types 19F, 19A, 19B and 19C, belongs to this group, and 47 
deserves particular attention since it globally accounts for a high percentage of IPD. Serogroup 19 48 
IPD are mainly caused by serotypes 19F and 19A, and, in particular, type 19F is one of the most 49 
common causes of IPD in children.
5
 The low immunogenicity of this serotype can be explained by 50 
the thickness of the 19F capsule and increased resistance to complement deposition, which is the 51 
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event required to opsonize pneumococci, facilitate phagocytosis and pathogen clearance. Serogroup 1 
19 has also attracted the interest of the research community because it represents one of the most 2 
significant cases to investigate cross-protective immunity. Capsules of serotypes 19F and 19A are 3 
isopolymers, differing only in one glycosidic linkage (glucose to rhamnose, Figure 1). The high 4 
similarity of the two capsular structures suggested the inclusion of only SP 19F in the formulation 5 
of the first glycoconjugate vaccine PCV7, since antibodies to some CPS may cross-react with 6 
related types providing protection against additional types. Indeed, this is what happened for the 7 
vaccine-type 6B, included in PCV7, since 6B-induced antibodies resulted able to cross protect 8 
against the structurally similar 6A CPS, with high effectiveness against 6A disease.
6
 Unfortunately, 9 
antibodies elicited by 19F antigen present in PCV7 provided limited cross-reactive protection 10 
against 19A disease, with the consequence of increasing non-vaccine 19A serotype carriage and 11 
virulence among population in a process defined “serotype replacement”.7 Indeed, most of the 12 
PCV7 recipients achieved a significant concentration of antibodies for the vaccine-associated 13 
serotype, but the absence of 19A opsonophagocytic activity indicates that such antibodies are not-14 
functional against 19A.
8
 The immunogenicity of the19F vaccine serotype, and the level of cross-15 
opsonophagocytic antibodies can be influenced by the conjugation method used to connect the 16 
antigenic saccharide fragment to the T-helper peptide, like reductive amination vs cyanylation.
9
 The 17 
lack of antibody-related cross-protection between serotypes 19F and 19A may be alternatively 18 
related to conformational differences between the two CPS structures.
10
 Of note, the problem to 19 
induce protection against 19A disease was overcome after the replacement of PCV7 with PCV13, 20 
that contains antigenic CPSs of both serotypes 19A and 19F. Remarkably, a higher level of serotype 21 
19F IgG was found in the sera of patients immunized with PCV13 with respect to PCV7 recipients, 22 
suggesting a contribution of cross-reactive 19A antibodies to the higher 19F opsonophagocytic 23 
activity titers induced by PCV13.
8
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Figure 1: Structures of serotypes 19F and 19A capsular polysaccharides 26 
 27 
Molecular approaches investigating the structural and chemical determinants of the cross reactivity 28 
between 19F and 19A serotypes have never been reported. Nonetheless, this knowledge may be 29 
useful to elucidate the mechanism responsible for immunoreactivity. 19F and 19A CPSs are linear 30 
biopolymers made up of trisaccharide repeating units linked through phosphodiester bridges. Each 31 
trisaccharide is composed by a -D-ManpNAc-(14)--D-Glcp disaccharide linked to C2 or C3 of 32 
an -L-Rha unit respectively (Figure 1). In this framework, we report the synthesis of compound 1, 33 
the trisaccharide repeating unit of SP 19A, functionalized at the reducing end with an aminopropyl 34 
linker, in turn obtained from protected trisaccharide 2 (Figure 2). Our strategy is based on the 35 
development of a new route for the synthesis of an aminopropyl functionalized rhamnosyl acceptor, 36 
compound 3 (Scheme 1). Furthermore, in search of the most straightforward approach towards 19A 37 
trisaccharide, we explored two alternative synthetic strategies, based on different disconnections 38 
between the three monosaccharides which make up the final trisaccharide. In particular, 39 
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trisaccharide 1 was assembled with higher yields when the -Glc-(13)-Rha disaccharide was 1 
glycosylated with a glucose moiety, followed by epimerization at C2. 2 
Finally, we evaluated the binding affinity of trisaccharide 1 towards anti-19A and anti-19F sera, to 3 
investigate the role of the carbohydrate portion of the repeating unit in the antibody binding affinity. 4 
Trisaccharide 1 showed a similar and moderate activity towards both sera, indicating that a limited 5 
cross recognition exists at the level of the single repeating unit. 6 
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Figure 2: Structures of the target compound 1 and its precursor 2 8 
 9 
2. Results and discussion 10 
2.1 Chemistry 11 
A key point in our synthetic strategy towards compound 1 has been the preparation of protected 12 
trisaccharide 2 as the direct precursor of the target derivative. Compound 2 is a very versatile 13 
molecule, which allows access to both the trisaccharide repeating unit of SP 19A (the goal of this 14 
work), and, in principle, to oligomeric and/or shifted fragments of SP 19A CPS. Elongation at the 15 
upstream residue of the trisaccharide can be performed after selective reductive opening of the 16 
benzylidene group. The functionalization at the reducing end with a 3-aminopropyl linker has been 17 
designed to allow conjugation to carrier proteins
11
 or the preparation of multivalent systems
12,13
 18 
appropriate for the in-vivo evaluation of the immunogenic activity of 19A CPS-related saccharide 19 
antigens. In this frame of thoughts, we have planned the synthesis of rhamnosyl acceptor 3, with the 20 
aminopropyl linker already installed,
14
 in order to avoid the glycosylation of the aglycon acceptor at 21 
a later stage of the synthetic route. 22 
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Scheme 1: Reagents and conditions: a. N-Z-3-aminopropanol, BF3Et2O, DCM, 0 °C to rt, 75%; b. 24 
MeONa, MeOH, 93%; c. TrCl, Py, 60 °C; BnBr, NaH, 64%; CF3COOH, DCM/MeOH, 90%. 25 
 26 
To this aim, tetraacetyl rhamnopyranoside 4
15
was glycosylated with N-Z-3-aminopropanol in the 27 
presence of boron trifluoride etherate to give the rhamnose aminopropyl glycoside 5 in 75% yield 28 
(Scheme 1). Zemplen deacetylation afforded deprotected rhamnoside 6 (93%), which was 29 
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regioselectively tritylated at position 3 by treatment with trityl chloride at high temperature, and 1 
then benzylated in 64% yield over two steps. Finally, the trityl group was removed by treatment 2 
with trifluoroacetic acid to give rhamnoside acceptor 3 in 90% yield. 3 
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Scheme 2: Reagents and conditions: a. TESOTf, DCM, - 20 °C, 93%; b. Et3SiH, BF3Et2O, DCM, 5 
0 °C, ms, 60%; c. TMSOTf, DCM, - 20 °C, ms, 88%; d. MeONa, MeOH, DCM, 89%; e. Im2SO2, 6 
NaH, DMF, - 40 °C, 85%; f. NaN3, DMF, 80 °C, 80%; g. Zn, AcOH/Ac2O, THF, 62%; h. H2, 7 
Pd(OH)2, HCl, AcOEt, MeOH, quant. 8 
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 1 
Two different disconnection strategies are possible for the construction of the 19A trisaccharide 2 
repeating unit (Figure 2), and all the syntheses previously reported are based on a A-B + C 3 
approach, where a preformed -ManNAc-(14)-Glc (A-B) disaccharide is coupled with a 4 
rhamnosyl acceptor (C).
16,17,18,19
 Based on our previous experience on the synthesis of the 5 
trisaccharide related to SP 19F CPS,
20,21
 we first followed the alternative B-C + A pathway in which 6 
an -Glc-(13)-Rha (B-C) disaccharide is initially formed in high selectivity, then -glycosylated 7 
with a glucose moiety (A) which is finally epimerized to N-acetyl-mannosamine. 8 
Rhamnosyl acceptor 3 was thus glycosylated at position 3 with 2,3-O-benzyl-4,6-O-benzylidene 9 
glucosyl trichloroacetimidate donor 8
22
 under the catalysis of triethylsilyl triflate (Scheme 2). The 10 
aminopropyl disaccharide 9 was recovered in excellent yield (93%) and complete -selectivity. 11 
Reductive opening of the benzylidene acetal to the corresponding 6-O-benzyl ether was next 12 
accomplished by treatment of 9 with triethylsilane in the presence of boron trifluoride-diethyl 13 
ether complex to give disaccharide acceptor 10 in good yield. 14 
The desired trisaccharide scaffold was obtained through a high yield glycosylation between the 2-15 
O-acetyl-3-O-benzyl-4,6-O-benzylidene glucosyl trichloroacetimidate donor 11
23
 and 16 
disaccharide acceptor 10 to give compound 12. The -selectivity was guaranteed by the 17 
anchimeric assistance offered by the acetyl group at position 2 of glucose 11. Trisaccharide 12 18 
was finally subjected to the synthetic sequence that allows gluco to manno epimerization. The 19 
acetyl group was initially removed to give unprotected 13 through Zemplen de-acetylation. 20 
Compound 13 was then reacted with sulfonyldiimidazole in the presence of sodium hydride to 21 
yield saccharide 14, which was subjected to nucleophylic displacement with sodium azide to 22 
give mannoside 15. The newly established manno configuration was confirmed by the broad 23 
1
H-NMR singlet for the anomeric proton of mannose. Finally, the azido group was reduced with 24 
Zinc in the presence of acetic acid/acetic anhydride to give the fully protected trisaccharide 2, 25 
which upon hydrogenolysis gave the target trisaccharide 1 in quantitative yield. Overall, the 26 
desired trisaccharide 1 was obtained starting from the properly protected monosaccharide 27 
donors 8 and 11 and the rhamnosyl acceptor 3 in 18% overall yield over 8 steps. 28 
With the goal of developing a solid protocol to trisaccharide 1, we next planned to test the 29 
feasibility of the alternative A-B + C disconnection strategy, which offers the advantage to reduce 30 
the number of steps on the already formed trisaccharide scaffold. To this aim, we decided to exploit 31 
a new synthetic strategy to obtain thio-disaccharide 16 for the glycosylation of the aminopropyl 32 
rhamnosyl acceptor 3. This approach is based on our consolidated protocols for the construction of 33 
the -mannoside linkage (Scheme 3). In this framework, disaccharide 18 was initially formed in a 34 
stereoselective fashion through a high yield glycosylation (86%) between phenylthio glucoside 17
24
 35 
and trichloroacetimidate donor 11. Next, epimerization at the C2’ of disaccharide 18, and the 36 
introduction of the acetamido group gave compound 16 in 35% overall yield over 4 steps. In detail, 37 
compound 18 was initially de-acetylated to 19, then the hydroxy group was activated in high yield 38 
as imidazylate and subjected to azide displacement with sodium azide to give mannoside 21, 39 
followed by azide reduction and N-acetylation. Glycosylation with rhamnosyl acceptor 3 was 40 
promoted using silver triflate–N-iodosuccinimide system as previously described,19 and gave 41 
protected trisaccharide 2 in satisfactory yields but low stereoselectivity (/ = 1:2). Compound 2 42 
was finally quantitatively deprotected to the target compound 1. The overall yield of the second 43 
synthetic strategy to compound 1, starting from the suitable building blocks 11, 17 and 3, is 6% 44 
over 7 steps. In general, this A-B + C strategy shows an efficient and easy linear synthesis of the -45 
mannosylated thioglycosyl-donor 16, but suffers from moderate yields and low stereoselectivity in 46 
the final glycosylation of rhamnose 3. 47 
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2.2 Biology  7 
The ability of increasing concentrations (from 10
-7
-10
0
 mg/mL) of the newly synthetized 8 
trisaccharide to inhibit the binding between 19A polysaccharide coated onto plates (positive 9 
control) and the anti 19A rabbit polyclonal antibody was evaluated by competitive ELISA. To 10 
evaluate the cross-reactivity against 19F serotype, competitive ELISA was done using native 19F 11 
polysaccharide and 19F reference serum. Figure 3 shows the inhibition curves obtained with 12 
compound 1, under evaluation in both systems. The relative efficacy of compound 1 was calculated 13 
by measuring the maximum effect elicited in each system, while the concentration that produces 14 
50% of the maximum effect (EC50) was taken as indirect index of its relative potency (Figure 3). 15 
As expected the natural polysaccharide exhibited higher efficacy (100% inhibition at 10
-1
 mg/mL) 16 
and affinity (EC50 = 9.1x10
-5
 mg/mL) than synthetized compound (41% inhibition at 10
0
 mg/mL 17 
and EC50 =1.3 x 10
-3
) confirming that saccharide chain length seems to be important for their 18 
biological activity. The low effectiveness of the newly synthetized compound could be related to its 19 
relative weak avidity, since short chain lengths saccharide antigens, like a trisaccharide, have 20 
decreased strength of antibody-antigen binding. The single repeating unit of 19A polysaccharide 21 
displayed inhibitory properties also in 19F system. The trisaccharide was slightly both more 22 
effective and potent in 19A than in 19F system (41% and 32% of inhibition for 19A and 19F 23 
respectively; EC50 1.3 x 10
-3
 and 2.7 x 10
-2
 for 19A and 19F respectively). These data suggest that 24 
differences in structures of the 19A and 19F trisaccharides are almost negligible at the repeating 25 
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unit level, and a level of cross reactivity exists. It is reasonable to speculate that saccharide 1 
fragments with chain length longer than compound 1, resulting in more complex structures, would 2 
contain multiple epitopes leading to an increase in specificity for 19A serum and a reduction in 3 
cross-reactivity versus 19F. 4 
 5 
Figure 3. Results of the Elisa experiments with compound 1. Concentration/response curves of 6 
compound 1 on the inhibition of the binding between the 19A (on the left) or 19F (on the right)  7 
native polysaccharides, coated onto the plates, and the anti-19A or anti-19F antibodies, respectively, 8 
were evaluated by a competitive ELISA method. 9 
 10 
3. Conclusions 11 
In conclusion, the synthesis of compound 1, an aminopropyl derivative of the trisaccharide 12 
repeating unit of SP 19A, has been developed exploiting rhamnosyl acceptor 3, already 13 
functionalized with an aminopropyl linker. We developed a new and more efficient synthetic route 14 
to the rhamnosyl acceptor, which allows to obtain compound 3 in 40% overall yield over four steps. 15 
Two different synthetic strategies were used to build trisaccharide 1, allowing a direct comparison 16 
among the two protocols. Based on our results, we suggest that the protocol based on the B-C + A 17 
strategy is more effective than the A-B + C one. The overall yield of assembly was around 20% for 18 
the first protocol, in contrast to the more modest 6% of the second approach, which is limited by the 19 
low selectivity in the glycosylation between disaccharide A-B and rhamnoside 3 (C). The results 20 
confirmed that the stereoselectivity of the reaction of -glucosylation is a function of the protecting 21 
groups on glucose, and the use of 4,6-O-benzylidene glucosyl donors, protected with no 22 
participating groups at the 2-position, are usually -selective.25 Indeed, the use of 4,6-O-23 
benzylidene glucosyl donor 8 allowed the formation of the -product in excellent yield. Overall, the 24 
first approach to trisaccharide 1 is solid and highly reproducible. Furthermore, the protected 25 
trisaccharide 2 is a valuable intermediate for the synthesis of shifted fragments of the CPS of SP 26 
19A: the elongation of the trisaccharide at the upstream residue is functional for the synthesis of 27 
oligomers functionalized at the downstream residue with the aminopropyl linker, useful for 28 
conjugation to proteins or multivalent scaffolds. We have also showed that compound 1, which 29 
possesses moderate inhibitory activity towards anti-19A antibodies, displays a comparable activity 30 
also towards anti-19F antibodies. This data suggests that the two sera are not capable of 31 
discriminating small differences in the structure of 19F and 19A trisaccharides. Since differences in 32 
 
 
 
 
 
 
 
 
 
 
 
 
       a
 The maximum inhibition elicited by each compound at 1 mg/ml.                         
a
 The maximum inhibition elicited by each compound at 1 mg/ml. 
Compound EC50 ± SEM (mg/mL) Max inhibition
a
 (%) 
19A PS (9.1 ± 1.2) × 10
-5
 100 
1 (1.3 ± 0.02) × 10
-3
 41 
Compound EC50 ± SEM (mg/mL) Max inhibition
a
 (%) 
19F PS (1.7 ± 0.006) × 10
-4
 100 
1 (2.7 ± 0.3) × 10
-2
 32 
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conformational preferences have been described for the repeating units of SP 19A and 19F,
10
 it is 1 
reasonable to assume that longer and structured fragments are needed to significantly affect the 2 
binding specificity of the antibodies to the saccharide antigens. 3 
 4 
4. Experimental Section: 5 
4.1 Synthetic procedures 6 
Standard laboratory procedures were followed to carry out the reactions and to prepare dry 7 
solvents.
26
 Optical rotations were measured with a Perkin-Elmer 241 polarimeter at 20 °C. 
1
H 8 
and 
13
C NMR spectra were recorded with a Bruker AVANCE-500 spectrometer at a sample 9 
temperature of 298 K.
27
 Mass spectrometric analyses were performed on a Thermo Quest 10 
Finnigan LCQ™DECA ion trap mass spectrometer; equipped with a Finnigan ESI interface. 11 
High-resolution mass spectra were collected by electrospray ionization (ESI) spectroscopy on a 12 
QTof SYNAPT G2Si Mass Spectrometer. NaH was washed with hexane three times prior to 13 
use. 14 
 15 
4.1.1.Synthesis of N-(benzyloxycarbonyl)aminopropyl 2,3,4-tri-O-acetyl--L-rhamnopyranoside (5) 16 
BF3  Et2O (5.0 mL, 39.45 mmol) was slowly added through a dropping funnel to a solution at 0 °C 17 
under argon of compound 4 (2.28 g, 6.86 mmol) and N-CBz-aminopropanol (3.59 g, 17.15 mmol) 18 
in dry CH2Cl2 (70 mL). The reaction was stirred at room temperature, monitored by TLC 19 
(hexane/ethyl acetate, 1:1) and appeared to be complete after 12 h. The reaction was washed with 20 
saturated NaHCO3 solution (2 x 100mL), and the combined aqueous phases extracted with AcOEt 21 
(2 x 100 mL). The combined organic layers were dried over Na2SO4 and concentrated. Purification 22 
by flash chromatography (hexane/AcOEt, 6:4) gave pure 5 (2.48 g, 75 %) as a colorless oil. []D
20
 = 23 
-43.6 (c = 0.5 in chloroform); 
1
H NMR (CDCl3):  = 7.40-7.30 (m ,5H, arom.), 5.29 (dd, 1 H, J2,3 = 24 
3.5 Hz, J3,4=10.0 Hz, H-3), 5.25 (dd, 1 H, J1,2 = 1.7 Hz, J2,3 = 3.5 Hz, H-2), 5.13 (s, 2H, CH2Ph), 25 
5.08 (t, 1 H, J3,4 = J4,5= 10.0 Hz, H-4), 4.95-4.88 (m, 1 H, NH), 4.73 (br s, 1 H, H-1), 3.91 – 3.83 26 
(m, 1 H, H-5), 3.81-3.74 (m, 1 H, H-a), 3.54-3.47 (m, 1H, H-a'), 3.37-3.29 (m, 2 H, 2 H-c), 2.17 (s 27 
,3 H, CH3CO), 2.06 (s, 3 H, CH3CO), 2.01(s, 3 H, CH3CO), 1.92-1.80 (m, 2 H, 2 H-b), 1.24 (d, 3 H, 28 
J5,6 = 6.3Hz, 3 H-6); 
13
C NMR (CDCl3):  = 170.2 (C=O), 170.0 (C=O), 169.9 (C=O), 156.4 (C=O, 29 
Cbz), 136.6 (arom), 128.5-128.1 (5 C arom), 97.5 (C-1), 71.1 (C-4 ), 69.8 (C-2 ), 69.1 (C-3 ), 66.7 30 
(CH2Ph), 66.5 (C-5), 65.8 (C-a), 38.4 (C-c), 29.6 (C-b), 20.9 (CH3), 20.8 (CH3), 20.7 (CH3), 31 
17.4(C-6). MS (ESI) m/z (): 504.1 (100) [M+Na]+. HRMS (ESI): m/z calcd for C23H31NO10Na 32 
504.1846 [M+Na]
+
, found 504.1836. 33 
 34 
4.1.2.Synthesis of N-(benzyloxycarbonyl)aminopropyl -L-rhamnopyranoside (6) 35 
Compound 5 (2.40 g, 4.98 mmol) was dissolved in dry dichloromethane (50 mL) and sodium 36 
methoxide in dry methanol (0.2 M solution, 12 mL) was added. The reaction was stirred for 3h at 37 
room temperature, then it was neutralized with an ion exchange resin (Dowex 50 × 8, H
+
 form), 38 
filtered and concentrated. The crude was subjected to flash chromatography (CH2Cl2/MeOH, 9:1) to 39 
give compound 6 (1.64 g, 93 %) as a colorless oil. []D
20
 = -38.5 (c = 0.5 in chloroform)  40 
1
H NMR (MeOD):  =7.40-7.28 (m, 5H, arom.), 5.09 (br s,2H, CH2Ph), 4.67 (br s, 1H, H-1), 3.83-41 
3.80 (m,1H, H-2), 3.77-3.70 (m, 1H, H-a), 3.66 (dd, 1 H, J2,3 = 3.3 Hz, J3,4 = 9.5 Hz, H-3), 3.61-3.55 42 
(m, 1H, H-5), 3.47-3.41 (m, 1H, H-a), 3.38 (t, 1 H, J3,4 = J4,5 =9.5 Hz, H-4), 3.28-3.18 (m, 2H, 2 H-43 
c), 1.83-1.75 (m, 2H, 2 H-b), 1.27 (d, 3 H, J5,6 = 6.4Hz, 3 H-6); 
13
C NMR (MeOD):  = 157.5 44 
(C=O), 137.0 (arom), 128.1-127.4 (5 C arom), 100.3 (C-1), 72.6 (C-4), 71.0 (C-3), 70.9 (C-2), 68.4 45 
(C-5), 66.0 (CH2Ph), 64.5 (C-a), 37.6 (C-c), 29.4 (C-b), 16.6 (C-6). MS (ESI) m/z (): 378.1 (100) 46 
[M+Na]
+
, 732.8 (12) [2M+Na]
+
. HRMS (ESI): m/z calcd for C17H25NO7Na 378.1529 [M+Na]
+
, 47 
found 378.1526. 48 
 49 
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4.1.3. Synthesis of N-benzyl-N-benzyloxycarbonyl-3-aminopropyl 2,4-di-O-benzyl-3-O-trityl--L-1 
rhamnopyranoside (7) 2 
A mixture of 6 (1.60 g, 4.50 mmol), trityl chloride (2.51 g, 9.00 mmol) and dry pyridine (15 mL) 3 
was stirred at 60 °C for 20 h. After the addition of Et3N (2 mL), the reaction was diluted with 4 
EtOAc (50 mL) and washed with HCl 1N (2 x 50 mL). The combined aqueous phases were 5 
extracted with AcOEt (3 x 40 mL), and then the combined organics were washed with satd. 6 
NaHCO3 soln. (1 x 60 mL), dried over Na2SO4 and evaporated under reduced pressure. To a 7 
solution of the crude and benzyl bromide (3.2 mL, 27 mmol) in dry DMF (50 mL), NaH (60 % in 8 
oil, 1.21 g, 31.5 mmol) was added portionwise at 0 °C. The reaction was warmed to room 9 
temperature. After 5 h, an additional amount of NaH (60 % in oil, 0.34 g, 9.00 mmol) was added 10 
and the reaction stirred for 12 h. The mixture was quenched by carefully addition of MeOH (5 mL), 11 
then diluted with HCl 1N (100 mL), and extracted with AcOEt (3 x 100 mL). The combined 12 
organics were washed with brine (2 x 150 mL), dried over Na2SO4 and evaporated. The crude was 13 
purified through flash chromatography (hexane/ AcOEt, 82:25) to give product 7 (2.5 g, 64 %) as a 14 
light yellow viscous oil. []D
20
 = -8.7 (c = 0.5 in chloroform)  15 
1
H NMR (CDCl3):  = 7.65-7.10 (m, 35H, arom.), 5.25-5.00 (m, 3H, CH2Ph), 4.80-4.65 (m, 1H, 16 
CH2Ph), 4.55-4.35 (m, 3H, H-1 and CH2Ph), 4.30-4.15 (m, 2H, CH2Ph), 4.10 (dd, 1H, J2,3 = 2.6 Hz, 17 
J3,4 = 9.2 Hz, H-3), 3.90-3.70 (m, 1H, H-4), 3.65-3.35 (m, 2H, H-5 and H-a), 3.35-3.05 (m, 3H, H-a 18 
and 2 H-c), 2.45-2.25 (m, 1H, H-2), 1.75-1.55 (m, 2H, 2 H-b), 1.33(d, 3H, J5,6 = 6.2 Hz, 3 H-6); 
13
C 19 
NMR (CDCl3):  = 156.8 (C=O), 145.1-127.0 (42 C, arom), 97.2 (C-1), 87.4 (C trityl), 80.5 (C-4), 20 
77.9 (C-2), 75.3 (CH2Ph), 73.8 (C-3), 71.9 (CH2Ph), 69.1 (C-5), 67.2 (CH2Ph), 65.0 (C-a), 51.0 21 
(CH2Ph), 45.1-44.1 (m, C-c), 28.6-28.0 (m, C-b), 18.4 (C-6); MS (ESI) m/z (): 890.5 (100) 22 
[M+Na]
+
. HRMS (ESI): m/z calcd for C57H57NO7Na 890.4033 [M+Na]
+
, found 890.4029. 23 
 24 
4.1.4. Synthesis of N-benzyl-N-benzyloxycarbonyl-3-aminopropyl 2,4-di-O-benzyl--L-25 
rhamnopyranoside (3) 26 
To a solution of compound 7 (0.90 g, 1.04 mmol) in 21 mL of DCM/MeOH (6:1, v/v), 27 
trifluoroacetic acid (0.60 mL, 7.88 mmol) was added dropwise. The reaction was stirred at room 28 
temperature for 5 h, then quenched to neutrality through addition of TEA. The solvent was 29 
evaporated under reduced pressure, and the crude purified by flash chromatography (hexane/ 30 
AcOEt, 82:25) to give rhamnoside 3 (0.58 g, 90 %) as a colorless oil. []D
20
 = -13.8 (c = 0.1 in 31 
chloroform)  32 
1
H NMR (CDCl3):  = 7.43-7.13 (m, 20 H, arom), 5.23-5.14 (m, 2H, CH2Ph), 4.92 (d, 1H, J = 11.1 33 
Hz, CH2Ph), 4.81-4.70 (m, 2H, H-1 and CH2Ph), 4.67 (d, 1H, J = 11.1 Hz, CH2Ph), 4.63-4.43 (m, 34 
3H, CH2Ph), 3.97-3.87 (m, 1H, H-3), 3.74-3.17 (m ,3H, H-2,5 and H-a), 3.48-3.25 (m, 4H, H-4, H-a 35 
and 2 H-c), 1.87-1.70 (m, 2H, 2 H-b), 1.33 (d, 3H, J5,6 = 6.2 Hz, 3 H-6); 
13
C NMR (CDCl3):  = 36 
156.2 (C=O), 138.6-127.3 (24 C, arom), 97.0 (C-1), 82.3 (C-4), 78.6 (C-2), 75.1 (CH2Ph), 73.0 37 
(CH2Ph), 71.7 (C-3), 67.2 (2C, C-5 and CH2Ph), 65.0 (C-a), 50.5 and 50.7 (d, NCH2Ph), 44.5 and 38 
43.7 (d, C-c), 28.3 and 27.8 (C-b), 18.0 (C-6); MS (ESI) m/z (): 684.4 (100) [M+Na]+. HRMS 39 
(ESI): m/z calcd for C38H43NO7Na [M+Na]
+
 648.2937, found 648.2936. 40 
 41 
4.1.5. Synthesis of N-benzyl-N-benzyloxycarbonyl-3-aminopropyl 2,3-di-O-benzyl-4,6-O-42 
benzylidene--D-glucopyranosyl-(13)-2,4-di-O-benzyl--L-rhamnopyranoside (9) 43 
A solution of glucosyl trichloroacetimidate 8 (0.70 g, 1.20 mmol) and rhamnoside 3 (0.30 g, 0.48 44 
mmol) in DCM (16 mL) was cooled at –20 °C, then triethylsilyl trifluoromethanesulfonate (0.1 M 45 
solution in DCM, 0.95 mL) was added dropwise. After 1,5 h the reaction was quenched by the 46 
addition of TEA, and allowed to warm to room temperature. The reaction was concentrated, then 47 
purified by flash chromatography (hexane/AcOEt, 8:2) to give disaccharide 9 (0.47 g, 93 %) as an 48 
oil. []D
20
 = +3.8 (c = 1 in chloroform). 
1
H NMR (CDCl3):  = 7.50-7.14 (m, 35H, arom.), 5.56 (s, 49 
1H, CHPh), 5.18 (br s, 2H, CH2Ph), 5.14 (d, 1H, J1’,2’ = 3,4 Hz, H-1’), 4.98-4.93 (m, 2H, CH2Ph), 50 
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4.85-4.41 (m, 9H, H-1 and CH2Ph), 4.21-4.04 (m, 4H, H-3, 6’ and 2Hs), 3.90-3.81 (m, 1H, H-2), 1 
3.69-3.55 (m, 6H, H-a, 4, 5, 2’, 6’ and 1H), 3.44-3.22 (m, 3H, 1 H-a and 2 H-c), 1.84-1.69 (m, 2H, 2 
2 H-b), 1.31 (br d, 3H, 3 H-6). 
13
C NMR (CDCl3):  = 163.3 (C=O), 138.6-126.2 (42C, arom.), 3 
101.3 (PhCH), 98.1 (C-1), 96.3 (C-1’), 82.6, 80.2, 79.2, 78.5, 76.7(C-3), 75.5 (2C, C-2 and CH2Ph), 4 
75.1 (CH2Ph), 73.7 (CH2Ph), 73.2 (CH2Ph), 69.0 (C-6’), 68.4, 67.2 (CH2Ph), 65.1 (C-a), 63.0, 50.52 5 
and 50.75 (NCH2Ph),43.73 and 44.50 (C-c), 27.81 and 28.30 (C-b), 18.0 (C-6). MS (ESI) m/z (): 6 
1079.1 (100) [M + 1 + Na]
+
. HRMS (ESI): m/z calcd for C65H69NO12Na 1078.4717 [M+Na]
+
, found 7 
1078.4712. 8 
 9 
4.1.6. Synthesis of N-benzyl-N-benzyloxycarbonyl-3-aminopropyl 2,3,6-tri-O-benzyl--D-10 
glucopyranosyl-(13)-2,4-di-O-benzyl--L-rhamnopyranoside (10) 11 
Compound 9 (0.45 g, 0.43 mmol) and 4 Å m.s. (0.45 g) were dissolved in DCM (10 mL), stirred at 12 
room temperature for 15 minutes, then the suspension was cooled at 0 °C. Triethylsilane (0.63 mL, 13 
4.30 mmol) was added, followed by the slow dropwise addition of BF3.Et2O (0.27 mL, 2.15 mmol). 14 
The reaction was stirred at 0 °C for 2 h, then quenched with triethylamine, diluted with DCM, 15 
filtered over celite, and concentrated in vacuo. The residue was purified by flash chromatography 16 
(Hexane/AcOEt, 8:2) to afford compound 10 (0.27 g, 60%) as an oil. []D
20
 = +10.8 (c = 1 in 17 
chloroform) 
1
H NMR (CDCl3):  = 7.40-7.20 (m, 35H, arom), 5.21-5.13 (m, 3H, H-1’ and CH2Ph), 18 
5.00-4.80 (m, 2H, CH2Ph), 4.84-4.83 (m, 11H, H-1 and CH2Ph), 4.14-4.06 (m, 1H, H-3), 4.04-3.97 19 
(m, 1H, H-5’), 3.96-3.80 (m, 2H, H-2, 3’), 3.74-3.45 (m, 7H, H-a, 4, 5, 2’, 4’, 6’a, 6’b), 3.42-3.19 20 
(m, 3H, 2 H-c and 1 H-a), 2.25-2.05 (br s, 1H, OH), 1.81-1.65 (m, 2H, 2 H-b), 1.33 (br s, 3H, 3 H-21 
6). 
13
C NMR (CDCl3):  = 156.4 (C=O), 138.8-127.3 (42C, arom.), 98.2 (C-1), 95.0 (C-1’), 81.3 22 
(C-3’), 80.1, 79.4, 76.0 (C-3), 75.5 (C-2), 75.2 (2C, CH2Ph), 73.4 (CH2Ph), 73.2 (CH2Ph), 73.0 23 
(CH2Ph), 71.2, 70.2 (C-5’), 69.5 (C-6’), 68.4, 67.2 (CH2Ph of Cbz), 65.1 (C-a), 50.5 and 50.8 24 
(NCH2Ph), 43.7 and 44.5 (C-c), 27.8 and 28.3 (C-b), 18.1 (C-6). MS (ESI) m/z (): 1080.1 (100) 25 
[M+Na]
+
. HRMS (ESI): m/z calcd for C65H71NO12Na 1080.4874 [M+Na]
+
, found 1080.4883. 26 
 27 
4.1.7. Synthesis of N-benzyl-N-benzyloxycarbonyl-3-aminopropyl 2-O-acetyl-3-O-benzyl-4,6-O-28 
benzylidene--D-glucopyranosyl-(14)-2,3,6-tri-O-benzyl--D-glucopyranosyl-(13)-2,4-di-O-29 
benzyl--L-rhamnopyranoside (12) 30 
A suspension of 2-O-acetyl-glucosyl trichloroacetimidate 11 (0.42 g, 0.78 mmol), disaccharide 10 31 
(0.23 g, 0.22 mmol) and 4 Å m.s. (0.23 g) in DCM (7 mL) was stirred for 0.15 min at room 32 
temperature, then cooled at –20 °C. Triethylsilyl trifluoromethanesulfonate (0.1 M solution in 33 
DCM, 0.44 mL) was added dropwise and the disappearance of the starting material was followed by 34 
TLC (Toluene/Acetone, 7:3; hexane/AcOEt, 7:3). After 1.5 h, the reaction was quenched with 35 
triethylamine, diluted with DCM, filtered over Celite, and the solvent evaporated. The crude 36 
product was purified by flash chromatography (hexane/AcOEt, 8:2) to give 12 (0.28 g, 88%) as an 37 
amorphous solid. []D
20
 = +5.9 (c = 1 in chloroform). 
1
H NMR (CDCl3):  = 7.53-7.10 (m, 45H, 38 
arom.), 5.48 (s, 1H, PhCH), 5.23-5.13 (m, 3H, H-1’ and CH2Ph), 4.97-4.82 (m, 4H, H-2’’ and 39 
CH2Ph), 4.76 (d, 2H, CH2Ph), 4.72-4.53 (m, 7H, H-1 and CH2Ph), 4.52-4.44 (m, 3H, H-1’’ and 40 
NCH2Ph), 4.29-4.22 (m, 1H, CH2Ph), 4.17-4.11 (m, 1H, H-6a’’), 4.08-3.99 (m, 1H, H-3), 3.99-3.91 41 
(m, 3H, H-3’, 4’, 5’), 3.91-3.82 (m, 1H, H-2), 3.74-3.53 (m, 6H, H-a, 4, 5, 2’, 6a’, 4’’), 3.51-3.36 42 
(m, 3H, H-6b’, 3’’, 6b’’), 3.35-3.21 (m, 3H, 1 H-a and 2 H-c), 3.18-3.10 (m, 1H, H-5’’), 1,82 (s, 43 
3H, COCH3), 1.81-1.67 (m, 2H, 2 H-b), 1.22 ( br d, 3H, 3 H-6). 
13
C NMR (CDCl3):  = 168.9 44 
(C=O), 139.3-126.0 (54C, arom.), 101.1 (CHPh), 100.8 (C-1’’), 98.2 (C-1), 96.5 and 96.3 (C-1’), 45 
81.6 (C-4’’), 80.1, 79.9, 79.2, 78.7, 77.4 (C-3), 76.7, 76.1 (C-2), 75.0 (CH2Ph), 74.9 (CH2Ph), 74.0 46 
(CH2Ph), 73.6 (CH2Ph), 73.3 (2C, C-2’’ and CH2Ph), 73.2 (CH2Ph), 70.7, 68.6 (C-6’’), 68.2, 67.6 47 
(C-6’), 67.2 (CH2Ph), 65.9 (C-5’’), 65.1 (C-a), 50.8 and 50.5 (NCH2Ph), 44.6 and 43.7 (C-c), 28.3 48 
and 27.9 (C-b), 20.8 (CH3CO), 18.0 (C-6). MS (ESI) m/z (): 1463.5 (100) [M + 1 + Na]
+
. HRMS 49 
(ESI): m/z calcd for C87H93NO18Na 1462.6290 [M+Na]
+
, found 1462.6276. 50 
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 1 
4.1.8. Synthesis of N-benzyl-N-benzyloxycarbonyl-3-aminopropyl 3-O-benzyl-4,6-O-benzylidene--2 
D-glucopyranosyl-(14)-2,3,6-tri-O-benzyl--D-glucopyranosyl-(13)-2,4-di-O-benzyl--L-3 
rhamnopyranoside (13) 4 
To a stirred solution of 12 (0.27 g, 0.19 mmol) in DCM/MeOH 1:1 (6 mL) sodium methoxide in 5 
methanol (1 M solution, 0.19 mL) was added. The reaction was stirred for 48 h at room 6 
temperature, then it was neutralized with an ion exchange resin (Dowex 50 × 8, H
+
 form), filtered 7 
and concentrated. The crude product was subjected to flash chromatography (hexane/AcOEt, 7:3) to 8 
give pure 13 (0.24 g, 89%) as an amorphous solid. []D
20
 = +15.3 (c = 1 in chloroform). 
1
H NMR 9 
(CDCl3):  = 7.52-7.16 (m, 45H, arom.), 5.48 (s, 1H, PhCH), 5.24-5.11 (m, 2H, H-1’ and CH2Ph), 10 
5.00-4.61 (m, 10H, H-1 and CH2Ph),  4.61-4.41 (m, 4H, CH2Ph), 4.37 (d, 1H, J1’’,2’’ = 7,5 Hz, H-11 
1’’), 4.33-4.28 (m, 1H, CH2Ph), 4.12-3.95 (m, 5H, H-3, 3’, 4’, 5’, 6a’’), 3.89-3.80 (m, 1H, H-2), 12 
3.80-3.74 (m, 1H, H-6a’), 3.74-3.58 (m, 5H, H-a, 4, 5, 2’), 3.58-3.51 (t, 1H, J3’’,4’’ = J4’’,5’’ = 9.3 Hz, 13 
H-4’’),3.51-3.37 (m, 3H, H-6b’, 3’’, 6b’’),3.37-3.21 (m, 4H, H-a, 2’’ and 2 H-c), 3.11-3.04 (m, 1H, 14 
H-5’’), 1.85-1.60 (m, 3H, 2 H-b and OH), 1.35 (d, 3H, J = 5.7 Hz, 3 H-6). 
13
C NMR (CDCl3):  = 15 
157.7 (C=O), 128.4-126.0 (54C, arom), 103.4 (C-1’’), 101.2 (CHPh), 98.3 (C-1), 94.5 (br s, C-1’), 16 
81.2 (C-4’’), 80.6, 80.3 (C-3’’), 80.0, 79.1 (C-2’), 77.4, 76.1 (C-3), 75.2 (2C, C-2, 2’’), 75.1-73.3 17 
(6C, CH2Ph), 70.0 (C-5’), 68.7 (C-6’’), 68.4, 68.2 (C-6’), 67.2 (CH2Ph), 66.1 (C-5’’), 65.2 (C-a), 18 
50.6 (br s, NCH2Ph), 44.5 and 44.4 (C-c), 27.9 and 27.6 (C-b), 18.0 (C-6). MS (ESI) m/z (): 19 
1420.7 (100) [M+NaM+Na]
+
. HRMS (ESI): m/z calcd for C85H91NO17Na 1420.6185 [M+Na]
+
, 20 
found 1420.6194. 21 
 22 
4.1.9. Synthesis of N-benzyl-N-benzyloxycarbonyl-3-aminopropyl 3-O-benzyl-4,6-O-benzylidene-2-23 
O-(N-imidazole-1-sulfonyl)--D-glucopyranosyl-(14)-2,3,6-tri-O-benzyl--D-glucopyranosyl-24 
(13)-2,4-di-O-benzyl--L-rhamnopyranoside (14) 25 
NaH (60 % in oil, 0.070 g, 1.76 mmol) was added to a stirred solution of compound 13 (0.23 g, 0.16 26 
mmol) in dry DMF (3.5 mL) at room temperature. After 1 h, the suspension was cooled at –40 °C 27 
and 1,1’-sulfonyl-diimidazole (0.22 g, 1.12 mmol) in dry DMF (1.5 mL) was added. After 24 h the 28 
reaction mixture was quenched with MeOH and allowed to warm to room temperature, then diluted 29 
with water (40 mL). The mixture was extracted with AcOEt (3 x 50 mL). The combined organic 30 
layers were washed with brine, dried over Na2SO4, filtered and evaporated. Flash chromatography 31 
(hexane/AcOEt, 7:3) of the crude product gave trisaccharide 14 (0.21 g, 85%) as an amorphous 32 
solid. []D
20
 = +1.8 (c = 1 in chloroform). 
1
H NMR (CDCl3):  = 7.94 (br s, 1H, Im), 7.53-7.10 (m, 33 
45H, arom), 7.00 (m, 2H, Im), 5.46 (s, 1H, PhCH), 5.25-5.12 (m, 3H, H-1’ and CH2Ph), 4.97 (d, 34 
1H, J = 11.1 Hz, CH2Ph), 4.85-4.58 (m, 10H, H-1and CH2Ph), 4.58-4.44 (m, 4H, H-2’’ and 35 
CH2Ph), 4.32 (d, 1H, J1’’,2’’ = 7,9 Hz, H-1’’), 4.23 (dd, 1H, J5’’,6’’ = 4,9 Hz, J6a’’,6b’’ = 10.6 Hz, H-36 
6a’’), 4.16-4.09 (m, 1H, CH2Ph), 4.09-3.80 (m, 5H, H-2, 3, 3’, 4’, 5’), 3.75-3.52 (m, 5H, H-a, 4, 5, 37 
2’,4’’), 3.52-3.20 (m, 7H, H-a’, c, c’, 6a’, 6b’, 3’’, 6b’’), 3.10-2.98 (m, 1H, H-5’’), 1.91-1.69 (m, 38 
2H, 2 H-b), 1.29-1.21 (br d, 3H,3 H-6). 
13
C NMR (CDCl3):  = 155.6 (C=O), 139.1-136.5 (9C, 39 
arom), 136.8 (C Im),129.2-126.0 (46C, arom.), 118.6 (C Im), 101.4 (CHPh), 98.6 (C-1’’), 98.2 (C-40 
1), 97.1 (br s, C-1’), 85.7 (C-2’’), 81.9 (C-4’’), 80.3 (br s, C-4), 79.5 (C-3’), 79.2 (C-2’), 78.4 (br s, 41 
C-3), 76.7 (C-3’’), 76.5 (br s, C-2), 76.2 (C-4’), 75.2 (2C, CH2Ph), 74.6 (br s, CH2Ph), 74.3 42 
(CH2Ph), 73.6 (CH2Ph), 73.1 (br s, CH2Ph), 70.2 (C-5’), 68.4 (C-6’’), 68.3 (C-5), 67.3 (C-6’), 67.2 43 
(CH2Ph), 65.7 (C-5’’), 65.2 (C-a), 50.8 and 50.5 (NCH2Ph), 44.6 and 43.7 (C-c), 28.4 and 27.9 (C-44 
b), 18.0 (C-6). MS (ESI) m/z (): 1550.3 (100) [M+NaM+Na]+. HRMS (ESI): m/z calcd for 45 
C88H93N3O19NaS 1550.6022 [M+Na]
+
, found 1550.6055. 46 
 47 
4.1.10. Synthesis of N-benzyl-N-benzyloxycarbonyl-3-aminopropyl 2-azido-3-O-benzyl-4,6-O-48 
benzylidene-2-deoxy--D-mannopyranosyl-(14)-2,3,6-tri-O-benzyl--D-glucopyranosyl-(13)-49 
2,4-di-O-benzyl--L-rhamnopyranoside (15) 50 
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To a stirred solution of 14 (0.20 g, 0.13 mmol) in dry DMF (4 mL), sodium azide (0.085g, 1.30 1 
mmol) was added and the resulting solution was heated at 80 °C. After 5 h, the reaction was cooled 2 
to room temperature, diluted with H2O and extracted with AcOEt (3 x 40 mL). The combined 3 
organic layers were dried over Na2SO4, filtered and evaporated. The crude product was purified by 4 
flash chromatography (hexane/AcOEt, 75:25) to give compound 15 (0.15g, 80%) as colourless oil 5 
[]D
20
 = -4.1 (c = 1 in chloroform). 
1
H NMR (CDCl3):  = 7.63-7.08 (m, 45H, arom.), 5.52 (s, 1H, 6 
PhCH), 5.25-5.16 (m, 2H, CH2Ph), 5.13 (d, 1H, J1’,2’ = 3.4 Hz, H-1’), 5.06 (d, 1H, J = 10.5 Hz, 7 
CH2Ph), 4.92 (d, 1H, J = 11.5 Hz, CH2Ph), 4.88-4.82 (m, 2H, CH2Ph), 4.82-4.75 (m, 2H, CH2Ph), 8 
4.74-4.45 (m, 8H, H-1 and CH2Ph), 4.34 (br s, 1H, H-1’’), 4.19-3.95 (m, 6H, H-3, 3’, 4’, 5’, 6a’’ 9 
and 1H x CH2Ph), 3.88 (t, 1H, J3’’,4’’ = J4’’,5’’ = 9.4 Hz, H-4’’), 3.85-3.76 (m, 1H, H-2), 3.75-3.58 (m, 10 
4H, H-a, 4, 5, 2’), 3.56-3.48 (m, 2H, H-2’’, 6b’’), 3.48-3.20 (m, 6H, H-a’, 6a’, 6b’, 3’’ and 2 H-c), 11 
3.00-2.92 (m, 1H, H-5’’), 1.88-1.72 (m, 2H, 2 H-b), 1.33 (d, 3H, J5,6 = 5.8 Hz, 3 H-6). 
13
C NMR 12 
(CDCl3):  = 156.6 and 156.1 (C=O), 137.9-126.0 (54C, arom.), 101.5 (CHPh), 99.7 (C-1’’), 98.4 13 
(C-1), 95.5 (br s, C-1’), 80.5 (C-3’), 79.8 (C-4), 79.0 (C-2’), 78.5 (C-4’’), 76.9 (C-3), 76.7 (C-4’), 14 
76.4 (C-3’’), 75.9 (C-2), 75.1 (CH2Ph), 74.7 (CH2Ph), 73.7 (CH2Ph), 73.6 (CH2Ph), 73.5 (CH2Ph), 15 
72.5 (CH2Ph), 69.7 (C-5’), 68.6 (C-5), 68.4 (C-6’’), 68.2 (C-6’), 67.2 (CH2Ph), 67.1 (C-5’’), 65.2 16 
(C-a), 63.2 (C-2’’), 50.8 and 50.6 (NCH2Ph), 44.6 and 43.7 (C-c), 28.3 and 27.9 (C-b), 18.0 (C-6). 17 
MS (ESI) m/z (): 1446.4 (100) [M + 1 + Na]+. HRMS (ESI): m/z calcd for C85H90N4O16Na 18 
1445.6250 [M+Na]
+
, found 1445.6246. 19 
 20 
4.1.11. Synthesis of phenyl 2-O-acetyl-3-O-benzyl-4,6-O-benzylidene--D-glucopyranosyl-(14)-21 
2,3,6-tri-O-benzyl-1-thio--D-glucopyranoside (18) 22 
Glucosyl trichloroacetimidate 11 (0.31 g, 0.57 mmol), phenylthio glucoside 17 (0.20 g, 0.37 mmol) 23 
and 4Å molecular sieves (0.20 g) were diluted in DCM (4 mL). The suspension was cooled at –20 24 
°C, then triethylsilyl trifluoromethanesulfonate (0.1 M solution in DCM, 0.74 mL) was added 25 
dropwise. The reaction was monitored by TLC (toluene/acetone, 9:1). After 1 h the reaction was 26 
quenched by the addition of TEA, diluted with AcOEt, and filtered over a Celite pad. After 27 
evaporation of the solvent, then crude was purified by flash chromatography (hexane/AcOEt, from 28 
8:2 to 7:3) to give disaccharide 18 (0.29 g, 86 %) as an amorphous white solid. []D
20
 = +20.6 (c = 1 29 
in chloroform). 
1
H NMR (CDCl3):  = 7.65-7.20 (m, 30H, arom), 5.50 (s, 1H, PhCH), 5.02-4.95 (m, 30 
2H, H- 2’ and CH2Ph), 4.92-4.70 (m, 5H, CH2Ph), 4.68-4.62 (m, 3H, H-1,1’ and CH2Ph), 4.52 (d, 31 
1H, J = 12.0 Hz, CH2Ph), 4.15 (dd, 1H, J5’,6’a = 5.0 Hz , J6'a,6’b = 10.5 Hz, H-6'a), 3.98 (t, 1H, J3,4 = 32 
J4,5 = 9.4 Hz, H-4), 3.79-3.77 (m, 2H, 2 H-6), 3.68 (t, 1H, J3’,4’ '= J4',5' = 9.3Hz, H-4'), 3.65-3.56 (m, 33 
2H, H-3, 3’), 3.52-3.43 (m, 2H, H-2, 6'b), 3.38(dt, 1H, J4,5 = 9.4 Hz, J5,6 = 2.6 Hz, H-5), 3.21 (dt, 34 
1H, J4’,5’ = 9.3 Hz, J5',6'a= 5.0 Hz, J5',6'b = 9.8 Hz, H-5'), 1,97 (s, 3H, CH3). 
13
C NMR (CDCl3):  = 35 
169.1 (C=O), 138.2-126.0 (36C, arom.), 101.2 (CHPh), 100.8 (C-1'), 87.4 (C-1), 84.7 (C-3), 81.7 36 
(C-4'), 80.2 (C-2), 79.0 (C-5), 78.6 (C-3'), 76.7 (C-4), 75.5 (CH2Ph), 75.4 (CH2Ph), 74.1 (CH2Ph), 37 
73.6 (CH2Ph), 73.3 (C-2'), 68.6 (C-6'), 67.9 (C-6), 66.1 (C-5'), 20.9(CH3). MS (ESI) m/z (): 947.6 38 
(100) [M+Na]
+
. HRMS (ESI): m/z calcd for C55H56O11NaS 947.3441 [M+Na]
+
, found 947.3439. 39 
 40 
4.1.12. Synthesis of phenyl 3-O-benzyl-4,6-O-benzylidene--D-glucopyranosyl-(14)-2,3,6-tri-O-41 
benzyl-1-thio--D-glucopyranoside (19) 42 
To a stirred solution of 18 (0.28 g, 0.30 mmol) in DCM (6 mL) sodium methoxide in methanol (0.1 43 
M solution, 0.60 mL) was added. The reaction was stirred for 17 h at room temperature, then it was 44 
neutralized with an ion exchange resin (Dowex 50 × 8, H
+
 form), filtered and concentrated. The 45 
crude product was subjected to flash chromatography (hexane/AcOEt, 8:2) to give pure 19 (0.20 g, 46 
75%) as an amorphous white solid. []D
20
 = +0.20 (c = 1 in chloroform). 
1
H NMR (CDCl3):  = 47 
7.60-7.27 (m, 30H, arom.), 5.49 (s, 1H, CHPh), 5.33 (s, 1H, OH), 4.98-4.94 (m, 2H, CH2Ph), 4.87-48 
4.78 (m, 3H, CH2Ph), 4.74-4.60 (m, 5H, H-1,1’ and CH2Ph), 4.10-4.01 (m, 2H, H-3, 6a), 3.97 (dd, 49 
1H, J5’,6’a = 5 Hz, J6'a,6’b = 10.4 Hz, H-6'a), 3.87-3.84 (m, 1H, H-6b), 3.68 (dd, 1H, J3,4 = J4,5 = 8.8 Hz, 50 
13 
 
H-4), 3.63-3.48 (m, 6H, H-2, 4, 5, 2’, 3’, 6’), 3.18-3.12 (m, 1H, H-5'). 13C NMR (CDCl3):  = 1 
138.8-126.0 (36 C, arom.), 103.6 (C-1'), 101.2 (CHPh), 87.5 (C-1), 85.5 (C-4), 81.3, 80.5, 80.4, 2 
78.8, 77.0 (C-3), 75.5, 75.3 (2 C, CH2Ph), 74.6 (CH2Ph), 73.6 (CH2Ph), 68.6 (C-6’), 68.5 (C-6), 3 
66.4 (C-5’). MS (ESI) 905.3 (100) [M+Na]+, 1787.9 (40) [2M+Na]+. HRMS (ESI): m/z calcd for 4 
C53H54O10NaS 905.3335 [M+Na]
+
, found 905.3331. 5 
 6 
4.1.13. Synthesis of phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-(N-imidazole-1-sulfonyl)--D-7 
glucopyranosyl-(14)-2,3,6-tri-O-benzyl-1-thio--D-glucopyranoside (20) 8 
NaH (60 % in oil, 0.13 g, 3.30 mmol) was added to a stirred solution of compound 19 (0.19 g, 0.22 9 
mmol) in dry DMF (6 mL) at room temperature. After 1 h, the suspension was cooled at –40 °C and 10 
1,1’-sulfonyl-diimidazole (0.44 g, 2.20 mmol) in dry DMF (3 mL) was added. After 2 h the reaction 11 
mixture was quenched with MeOH and allowed to warm to room temperature, then diluted with 12 
AcOEt (40 mL) and washed with brine (2 x 30 mL). The organic layers were dried over Na2SO4, 13 
filtered and evaporated. Flash chromatography (hexane/AcOEt, 8:2) of the crude product gave 14 
compound 20 (0.19 g, 86%) as a foamy solid. []D
20
 = -10.6 (c = 1 in chloroform). 
1
H NMR 15 
(CDCl3):  = 7.89 (s, 1H, H imidazole), 7.59-7.22 (m, 31H, arom.), 7.03 (s, 1H, H imidazole), 5.49 16 
(s,1H, CHPh), 4.89-4.75 (m, 6H, CH2Ph), 4.64-4.58 (m, 3H, H-1, 1’ and 1H of CH2Ph), 4.52 (t, 1H, 17 
J1',2' = J2',3' = 8.7 Hz, H-2'), 4.42 (d, 1H, J =11.8 Hz,1H of CH2Ph), 4.26 (dd, 1H, J5,6’a = 5.0 Hz, J6'a,6’b 18 
= 10.5 Hz, H-6’a), 4.06 (t, 1H, J3,4 = J4,5 = 9.5 Hz, H-4), 3.70-3.44 (m, 7H, H-2, 3, 6a, 6b, 3’, 4’, 19 
6’b), 3.18-3.07 (m, 2H, H-5, 5’). 13C NMR (CDCl3):  = 138.7-126.0 (38 C, 2 C imidazole and 36 C 20 
arom), 118.5 (C imidazole), 101.5 (CHPh), 98.4 (C-1'), 87.5 (C-1), 85.5 (C-2'), 84.1, 81.9, 80.3, 21 
78.1 (C-5), 77.0, 75.6, 75.5 (CH2Ph), 75.4 (CH2Ph), 74.5 (CH2Ph), 73.6 (CH2Ph), 68.4 (C-6’), 67.6 22 
(C-6), 65.9 (C-5’). MS (ESI) m/z (): 1035.2 (100) [M+Na]+. HRMS (ESI): m/z calcd for 23 
C56H56N2O12NaS2 1035.3172 [M+Na]
+
, found 1035.3165. 24 
 25 
4.1.14. Synthesis of phenyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy--D-glucopyranosyl-26 
(14)-2,3,6-tri-O-benzyl-1-thio--D-glucopyranoside (21) 27 
To a stirred solution of 20 (0.18 g, 0.18 mmol) in dry DMF (3.5 mL), sodium azide (0.12 g, 1.80 28 
mmol) was added and the resulting solution was heated at 85 °C. After 4 h, the reaction was cooled 29 
to room temperature, diluted with brine (30 mL) and extracted with AcOEt (3 x 20 mL). The 30 
combined organic layers were dried over Na2SO4, filtered and evaporated. The crude product was 31 
purified by flash chromatography (hexane/AcOEt, 75:25) to give compound 21 (0.13 g, 83%) as a 32 
foamy white solid. []D
20
 = -23.9 (c = 1 in chloroform). 
1
H NMR (CDCl3):  = 7.60-7.28 (m, 30H, 33 
arom.), 5.53 (s, 1H, CHPh), 5.01 (d, 1H, J = 10.5 Hz, 1H of CH2Ph), 4.88-4.76 (m, 4H, CH2Ph), 34 
4.73-4.70 (m, 2H, H-1’ and 1H of CH2Ph), 4.68-4.64 (m, 2H, H-1 and 1H of CH2Ph), 4.50 (d, 1H, J 35 
= 10.5 Hz, 1H of CH2Ph), 4.05-3.99 (m, 2H, H-3, 6’a), 3.94 (t, 1H, J3’,4’ = J4',5' = 9.5 Hz, H-4'), 3.86 36 
(dd, 1H, J1’,2’ = 1.1 Hz, J2',3 '= 3.6 Hz, H-2'), 3.81-3.78 (m, 2H, 2 H-6), 3.72 (t, 1H, J3,4= J4,5 = 8.9 Hz, 37 
H-3), 3.58-3.49 (m, 4H, H-2, 5, 3’, 6’b), 3.09-3.04 (m, 1H, H-5'). 13C NMR (CDCl3):  = 138.8-38 
126.0 (36C, arom.), 101.5 (CHPh), 100.3 (C-1'), 87.5 (C-1), 85.0 (C-4), 80.3, 78.5, 76.5 (C-4’), 39 
77.4 (C-3), 76.7, 75.5 (2C, CH2Ph), 73.7 (CH2Ph), 72.8 (CH2Ph), 68.8 (C-6), 68.3 (C-6'), 67.3 (C-40 
5'), 63.6 (C-2'). MS (ESI) m/z (): 930.3 (100) [M+Na]+, 1837.5 (20) [2M+Na]+. HRMS (ESI): m/z 41 
calcd for C53H53N3O9NaS 930.3400 [M+Na]
+
, found 930.3403. 42 
 43 
4.1.15. Synthesis of phenyl 2-acetamido-3-O-benzyl-4,6-O-benzylidene-2-deoxy--D-44 
glucopyranosyl-(14)-2,3,6-tri-O-benzyl-1-thio--D-glucopyranoside (16) 45 
A mixture of 21 (0.12 g, 0.13 mmol) and Zinc (0.43 g, activated with aq. 2% CuSO4) in 46 
THF/Ac2O/AcOH 3:2:1 (5 mL) was stirred for 1h at room temperature. The reaction was diluted 47 
with AcOEt and filtered over a Celite pad. Satd. aq. NaHCO3 was added (30 mL) and, after 48 
separation, the aqueous phases were extracted with AcOEt (2 x 20mL). The combined organics 49 
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were dried over NaSO4, filtered and concentrated. Flash chromatography (Hexane/AcOEt, 6:4) of 1 
the crude product gave pure 16 (0.080 g, 66%) as a foam. []D
20
 = -34.0 (c = 1 in chloroform)  2 
1
H NMR (CDCl3):  = 7.60-7.24 (m, 30H, arom.), 5.58 (br d, 1H, J = 9.1 Hz, NH), 5.50 (s, 1H, 3 
CHPh), 4.89-4.86 (m, 3H, CH2Ph), 4.77-4.67 (m, 5H, H-1’, 2’ and CH2Ph), 4.65 (d, 1H, J1,2 = 9.7 4 
Hz, H-1), 4.57-4.53 (m, 2H, CH2Ph), 4.18-4.06 (m, 2H, H-4,6’a), 3.84-3.77 (m, 2H, 2 H-6), 3.66-5 
3.58 (m, 3H, H-3, 4’, 6’b), 3.54-3.51 (m, 2H, H-2, 3’), 3.46-3.44 (m, 1H, H-5), 3.22-3.15 (m, 1H, 6 
H-5’), 1.87 (s, 3H, CH3). 
13
C NMR (CDCl3):  = 170.4 (C=O), 139.0-126.1 (36C, arom.), 101.6 7 
(CHPh), 100.1 (C-1'), 87.5 (C-1), 85.3, 80.6, 78.7 (C-5), 78.6, 76.5 (C-4), 75.8, 75.4 (CH2Ph), 75.2 8 
(CH2Ph), 73.5 (CH2Ph), 71.5 (CH2Ph), 68.7 (C-6), 68.6 (C-6’), 67.1 (C-5'), 50.4 (C-2'), 23.2 (CH3). 9 
MS (ESI) m/z (): 946.4 (100) [M+Na]+, 1869.7 (75) [2M+Na]+. HRMS (ESI): m/z calcd for 10 
C55H57NO10NaS 946.3601 [M+Na]
+
, found 946.3605. 11 
 12 
4.1.16. Synthesis of N-benzyl-N-benzyloxycarbonyl-3-aminopropyl 2-acetamido-3-O-benzyl-4,6-O-13 
benzylidene-2-deoxy--D-mannopyranosyl-(14)-2,3,6-tri-O-benzyl--D-glucopyranosyl-(13)-14 
2,4-di-O-benzyl--L-rhamnopyranoside (2) 15 
From compound 15: A mixture of 15 (0.14 g, 0.10 mmol) and Zinc (0.44 g, activated with aq. 2% 16 
CuSO4) in THF/Ac2O/AcOH 3:2:1 (5 mL) was stirred for 3h at room temperature. The reaction was 17 
diluted with AcOEt and filtered over a Celite pad. Satd. aq. NaHCO3 was added (30 mL) and, after 18 
separation, the aqueous phases were extracted with AcOEt (2 x 20mL). The combined organics 19 
were washed with brine, dried over NaSO4, filtered and concentrated. Flash chromatography 20 
(Hexane/AcOEt, 7:3) of the crude product gave pure 16 (0.091 g, 62%) as an amorphous glassy 21 
solid. 22 
From compound 16: A solution of 16 (0.06 g, 0.065 mmol) and 3 (0.08 g, 0.13 mmol) in dry DCM 23 
(2 mL) containing 4Å molecular sieves (0.15 g) was stirred at room temperature for 0.5 h.The 24 
suspension was cooled to -35 °C, and then NIS (0.022 g, 0.097 mmol) followed by AgOTf (8 mg, 25 
0.033 mmol) were added. After the addition, the reaction was allowed to warm to -10 °C and was 26 
stirred at that temperature. After 0.45 h, TLC (Hexane/AcOEt, 6:4) showed the disappearances of 27 
the donor. The reaction was diluted with DCM (30 mL) and filtered over a Celite pad. The organic 28 
solution was then washed with 10 % aq. Na2S2O3 (30 mL) and satd aq. NaHCO3 (30 mL). The 29 
organics were then dried over NaSO4, filtered and concentrated. The residue was purified by flash 30 
chromatography (Hexane/AcOEt, 7:3) to give first -2 (0.018 g), followed by -2 (0.037 g) with an 31 
overall glycosylation yield of 60%. []D
20
 = +0.77 (c = 0.5 in chloroform). 
1
H NMR (CDCl3):  = 32 
7.59-7.01 (m, 45H, arom.), 5.53-5.43 (m, 2H, 1H x CH2Ph and NH), 5.23-5.17 (m, 2H, CH2Ph), 33 
5.15 (d, 1H, J1’,2’ = 2.9 Hz, H-1), 4.95 (d, 1H, J = 11.7 Hz, 1 x CH2Ph), 4.89-4.74 (m, 4H, CH2Ph), 34 
4.74-4.46 (m, 10H, H-1, 2" and CH2Ph), 4.43 (br s, 1H, H-1"), 4.25-4.11 (m, 2H, H-6a’’ and 1 x 35 
CH2Ph), 4.07-4.01 (m, 2H, H-3, 3'), 3.99-3.92 (m, 2H, H-4’, 5’), 3.84 (br d, 1H, H-2), 3.75-3.58 (m, 36 
5H, H-a, 4, 5, 2’, 6b’’), 3.55 (t, 1H, J3",4" = J4",5" = 9.6Hz, H-4’’), 3.47-3.20 (m, 6H, H-a’, 6a’, 6b’, 37 
3’’ and 2 H-c), 3.13-3.03 (m, 1H, H-5’’), 1.87-1.73 (m ,5H, 2 H-b and CH3CO), 1.32 (d, 3H, J5,6 = 38 
6.0 Hz ,3 H-6). 
13
C NMR (CDCl3):  = 170.25 (C=O), 156.6 and 156.1 (C=O), 139.4-126.1 (54C, 39 
arom.), 101.6 (CHPh), 99.4 (C-1’’), 98.3 (C-1), 96.3 (C-1’), 80.8 (C-4’), 79.9 (C-4), 79.4 (C-2’), 40 
78.7 (C-4’’). 77.6 (br s, C-3’), 76.3 (C-2), 75.8 (C-3’’), 75.7 (C-3), 74.9 (CH2Ph),74.8 (CH2Ph), 41 
73.6 (CH2Ph), 73.4 (CH2Ph), 73.3 (CH2Ph), 71.3 (CH2Ph), 70.2 (C-5’), 68.7 (C-6’’), 68.5 (C-5), 42 
68.0 (C-6’), 67.2 (CH2Ph), 67.0 (C-5’’), 65.1 (C-a), 50.8 and 50.6 (2C, C-2’’ and NCH2Ph), 44.6 43 
and 43.7 (C-c), 28.3 and 27.9 (C-b), 23.1 (CH3CO), 18.1(C-6). MS (ESI) m/z (): 1461.9 (100) 44 
[M+Na]
+
. HRMS (ESI): m/z calcd for C87H94N2O17Na 1461.6450 [M+Na]
+
, found 1461.6449. 45 
 46 
4.1.17. Synthesis of 3-aminopropyl 2-acetamido-2-deoxy--D-mannopyranosyl-(14)--D-47 
glucopyranosyl-(13)--L-rhamnopyranoside hydrochloride salt (1) 48 
Compound 2 (0.080 g, 0.056 mmol) in AcOEt/MeOH/0.02M HCl, 1:1:1 (9 mL) was 49 
hydrogenolyzed over Pd(OH)2 (0.070 g) for 4 days. The mixture was filtered over pleated filter 50 
15 
 
paper, the filtrate was concentrated to 1 mL, and then lyophilized to give trisaccharide 1 (0.034 g, 1 
97%) as an amorphous white solid. []D
20
 = -19.6 (c = 0.5 in water). 
1
H-NMR (D2O):  = 4.98 (d, 2 
1H, J1’,2’'= 3.7 Hz, H-1’), 4.81 (br d, 1H, J1’’,2’’ = 1.3 Hz, H-1’’), 4.77 (br d, 1H, J1,2 = 1.7 Hz, H-1), 3 
4.47 (dd, 1H, J’’,2’’ = 1.4 Hz, J2",3" = 4.4Hz, H-2’’), 4.09-4.05 (m, 1H, H-2), 3.98-3.92 (m, 1H, H-5’), 4 
3.89-3.34 (m, 15H), 3.10-2.95 (m, 2H, 2 H-c), 1.99 (s, 3H, CH3CO), 1.95-1.87 (m, 2H, H-b), 1.23 5 
(d, 3H, 3 H-6). 
13
C NMR (D2O):  = 175.4 (C=O), 99.4 (2C, C-1, 1’’), 95.5 (C-1’), 78.6, 76.5 (C-6 
5’’), 75.9 (C-3), 71.9 (C-3’’), 71.5 (C-3’), 71.2 (C-2’), 70.2 (2C), 68.8, 66.8 (C-2), 66.7, 64.9 (C-a), 7 
60.4 (C-6’’), 59.7 (C-6’), 53.3 (C-2’’), 37.4 (C-c), 26.7 (C-b), 22.0 (CH3CO), 16.7 (C-6). MS (ESI) 8 
m/z (): 609.3 (100) [M+Na]+. HRMS (ESI): m/z calcd for C23H43N2O15 587.2663 [M+H]
+
, found 9 
587.2664. 10 
 11 
4.2. Biological test 12 
Competitive ELISA assay: 96-well flat-bottomed plates were incubated overnight at 4-8°C with a 13 
mixture of S. pneumoniae CPS 19A (1 mg/mL, Statents serum Institute, Artillerivej, Denmark) or 14 
19F (1 mg/mL,Sanofì-Aventis, France) and methylated human serum albumin (1 mg/mL). A 15 
solution of foetal calf serum (5%) in phosphate-buffered saline supplemented with Brij-35 (0.1%) 16 
and sodium azide (0.05%) was applied to the plates for blocking of nonspecific binding sites. The 17 
plates were incubated overnight at 4-8°C with a solution (1:200) of rabbit anti-19A or 19F, used as 18 
reference serum (Statents serum Institute, Artillerivej, Denmark). When trisaccharide was tested, it 19 
was added to each well immediately before the addition of the reference serum. The plates were 20 
then incubated with alkaline phosphatase conjugate goat anti-rabbit IgG (Sigma-Aldrich, Milan, 21 
Italy), stained with p-nitrophenylphosphate, and the absorbance was measured at 405 nm with an 22 
Ultramark microplate reader (Bio-Rad Laboratories S.r.l., Milan, Italy). 23 
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